InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the full record of transactions filed by Bruns Ingmar. Director active across 1 company, notably Zentalis Pharmaceuticals, Inc.. Aggregated, 2 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €44k. History available since 3 February 2025. The latest transaction was disclosed on 6 February 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
2 of 2 declarations